Morepen Laboratories Q4 FY25: Profit Falls 29%, Dividend

Results at a glance: revenue up, profit down

Morepen Laboratories Ltd. reported mixed consolidated results for the March quarter (Q4 FY25), with revenue growth but a sharp fall in profitability. Consolidated net profit declined 29.33% year-on-year to Rs 20.31 crore, compared with Rs 28.74 crore in Q4 FY24. Revenue from operations increased 10.11% year-on-year to Rs 465.85 crore from Rs 423.74 crore. The company’s commentary pointed to a challenging quarter where higher expenses and inflationary pressures affected profitability despite steady top-line growth. The reported set of numbers reinforced that operating leverage did not play out in the quarter as margins contracted.

Profitability pressure shows up in margin and EBITDA

The quarter’s operating performance was weaker than the revenue headline suggests. One set of results data showed EBITDA at Rs 42.6 crore in Q4 FY25, down 12.6% year-on-year from Rs 48.4 crore, with EBITDA margin at 9% versus 11.4% a year earlier. Another market report on the same quarter cited EBITDA at Rs 47 crore in Q4 FY25 versus Rs 53 crore in Q4 FY24, and EBITDA margin at 10% versus 12.3% last year. Across the reported figures, the direction was consistent: EBITDA fell and margins narrowed year-on-year. The company also flagged that rising costs and inflationary pressures weighed on profitability, aligning with the margin compression seen in the numbers.

PBT and EPS: bottom line weakness in the quarter

Profit before tax (PBT) in Q4 FY25 stood at Rs 25.71 crore, down 39.07% year-on-year from Rs 42.20 crore in Q4 FY24, as cited in the market update. For the quarter, one summary of results also listed total income at about Rs 466 crore and profit after tax (PAT) at about Rs 20 crore. Earnings per share (EPS) for Q4 FY25 was reported at Rs 0.37. These indicators collectively show that while Morepen delivered growth in sales, profitability and per-share earnings did not keep pace.

Expenses rose faster than income in Q4

A key driver of the weaker profitability was the increase in costs. The company reported total expenditure of Rs 444.75 crore in Q4 FY25, a 15% rise from Rs 385.1 crore in Q4 FY24. With total income for the quarter reported at Rs 470.46 crore in one disclosure (and revenue from operations at Rs 465.85 crore in another), the expense growth outpaced income growth. This gap helps explain the decline in PAT and the contraction in EBITDA margin.

Dividend returns after a long gap

Morepen Laboratories’ board approved a final dividend of Rs 0.20 per equity share (face value Rs 2) for the financial year ended March 31, 2025. The dividend was described as coming after a long gap, with one account noting a wait of 23 years and another noting 24 years since the last payout. The company also indicated the dividend is subject to approval by shareholders at the ensuing Annual General Meeting (AGM). As per the Hindi disclosure included in the source material, the record date had not been announced at the time of reporting and was to be communicated later. One dataset also translated the Rs 0.20 dividend into a dividend yield of 0.47%.

Stock reaction: initial drop, then recovery in trade

The results triggered mixed moves in the stock price across updates cited. In one market report, Morepen Laboratories shares slipped 2.83% to Rs 58.67 after the company reported the year-on-year decline in Q4 profit. Another update said the shares recovered over 5% from the day’s low of Rs 57.92 per share after results and the dividend announcement. Separately, one report said the stock closed 7.38% higher at Rs 60.38 on the BSE. Taken together, the trading updates suggest a volatile reaction, with investors weighing the sharp profit decline against the dividend announcement and revenue growth.

Business mix: API and medical devices referenced

The source material also referenced business segment contributions. Morepen’s API business was described as continuing to dominate, contributing Rs 989 crore, while the Medical Devices segment was stated at Rs 496 crore, growing 12% year-on-year. The article text did not specify the exact period for these segment figures, but they were presented as part of the broader update on the company’s operating performance. The mention highlights that APIs and medical devices remain key pillars in the business narrative.

Full-year snapshot: FY25 growth with mixed profit disclosures

For the full year, one report said Morepen Laboratories’ revenue rose 7.22% to Rs 1,812 crore in FY25 from Rs 1,690 crore in FY24. Another disclosure presented total income at Rs 1,830 crore for FY25 compared with Rs 1,704 crore in FY24. On profitability, one update stated FY25 net profit was the company’s “highest-ever” at Rs 118 crore, up 21.65% from Rs 97 crore in FY24. However, another disclosure in the same supplied text stated PAT for FY25 declined 4.3% to Rs 37.09 crore from Rs 38.79 crore in the previous year. The figures above are presented as they appear in the provided material and show that multiple summaries with differing bases were cited.

Key numbers table

Why the quarter matters for investors

The Q4 FY25 update matters because it shows a clear trade-off between growth and profitability in the near term. Revenue rose at a healthy double-digit rate, but the fall in EBITDA and the sharper decline in net profit signal margin headwinds. The reported rise in total expenditure and management’s reference to inflationary pressures support the view that costs rose faster than income in the quarter. At the same time, the dividend announcement drew attention because it marked a return of shareholder payout after a long period, subject to AGM approval and record date communication. Investors are likely to track whether margins stabilise in coming quarters and how the company manages cost inflation while sustaining revenue momentum.

Conclusion

Morepen Laboratories ended Q4 FY25 with revenue growth but weaker margins, leading to a 29.33% year-on-year fall in consolidated net profit to Rs 20.31 crore. The board-approved final dividend of Rs 0.20 per share added a positive headline, though it remains subject to shareholder approval at the upcoming AGM. Future updates, including the dividend record date and subsequent quarterly margin trends, will be key watchpoints for the market.